The inhibitors are then improved upon by a trial-and-error process in which structural modifications are made, assayed for binding affinity, and compared.
Unfortunately, technical and other considerations make assaying at more frequent time points impractical.
The solution was stored at 4°C covered in foil and used up to one week to make assay solutions.
To make assay plates with OP50, we concentrated a liquid culture of OP50 six times, spread 20 µl over their surface, and dried the plates for 15 minutes.
The requirement of other platforms for either surface immobilization and/or labeling steps makes assay development and species validation arduous, slow, and expensive.
A very practical consideration is that imaging can assess receptor expression at sites that are challenging to sample and assay, for example, bone metastases, where de-calcification can make assay of tumor gene products challenging.
LNAs make assay design nearly independent of miRNA GC content and compensates for many of the compromises one otherwise would have to make with a short miRNA target sequence of just ~22 nucleotides.
This could be a result of the similar coefficients of variation within and between days for the AR-CALUX assay making the assay less robust than the ER assay.
The presence of mature, uninfected DCs in infected cultures obviously makes assays that do not distinguish between latent infection and no infection very hard to interpret.
